$HCM #Hutchison China Meditech Hutchison China MediTech (Chi-Med): ASCO 2020 - savo and suru data drives regulatory progress: Hutchison China MediTech (Chi-Med) presented savolitinib and surufatinib data at the American Society of… https://t.co/u5ndUsgx1G #equity #stocks https://t.co/20H6OT9Kwo